ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2012
Targeting the endothelin axis in prostate carcinoma.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies.Clinical drug investigation · 2015Pooled it
- Endothelin-axis antagonism enhances tumor perfusion in pancreatic cancer.Cancer letters · 2022Article
- Endothelin receptors promote schistosomiasis-induced hepatic fibrosis via splenic B cells.PLoS pathogens · 2020Article
- Mesenchymal Stromal Cells: Emerging Roles in Bone Metastasis.International journal of molecular sciences · 2018Review
- Skeletal complications in cancer patients with bone metastases.International journal of urology : official journal of the Japanese Urological Association · 2016Review
- Activation of ETA Receptor by Endothelin-1 Induces Hepatocellular Carcinoma Cell Migration and Invasion via ERK1/2 and AKT Signaling Pathways.The Journal of membrane biology · 2016Article
- New therapeutic targets for cancer bone metastasis.Trends in pharmacological sciences · 2015Review
- Recent advances in bone-targeted therapies of metastatic prostate cancer.Cancer treatment reviews · 2014Review
- Research on tumorigenicity of cinnamaldehyde in melanoma cell lines and its mechanism.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.Cancer chemotherapy and pharmacology · 2014Article
- The prognostic value of Smad4 mRNA in patients with prostate cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer.Journal of tissue engineering · 2014Article
- Article
- Prognostication of prostate cancer based on NUCB2 protein assessment: NUCB2 in prostate cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Clinical significance of NUCB2 mRNA expression in prostate cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.Asian journal of andrology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignancy in men in Western countries. Until the last decade, the main available therapeutic options were based on hormonal therapy. For castration-refractory prostate carcinoma, from 2004, the combination of chemotherapy with docetaxel and prednisone has shown to improve survival in this subset of patients. Many agents have been tested either alone or in combination with this standard therapy, trying to find synergistic effects between drugs, and to target specific pathways that influence tumor growth, invasiveness, angiogenesis, and the development of distant metastasis. Endothelin antagonists have been recently studied, as they can get involved in many of these oncogenic pathways, and results are encouraging; nevertheless, the right setting to use them, whether to use them in monotherapy or in combination with other agents, and if they really improve the survival of our patients, are questions that remain to be addressed. In this review, we summarize the role of endothelins in tumoral biology and specifically in prostate carcinoma natural history, and the results obtained in the clinical trials involving this new therapeutic group.
Indexed as
Identifiers
22203496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.